[{"address1": "42127 Pleasant Forest Court", "city": "Ashburn", "state": "VA", "zip": "20148-7349", "country": "United States", "phone": "703 980 4182", "website": "https://quoinpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. operates as a subsidiary of Skinvisible, Inc.", "fullTimeEmployees": 4, "maxAge": 86400, "priceHint": 4, "previousClose": 0.623, "open": 0.6239, "dayLow": 0.6112, "dayHigh": 0.6239, "regularMarketPreviousClose": 0.623, "regularMarketOpen": 0.6239, "regularMarketDayLow": 0.6112, "regularMarketDayHigh": 0.6239, "beta": 2.041, "forwardPE": -0.44057554, "volume": 12286, "regularMarketVolume": 12286, "averageVolume": 60512, "averageVolume10days": 47440, "averageDailyVolume10Day": 47440, "ask": 0.615, "askSize": 100, "marketCap": 2437333, "fiftyTwoWeekLow": 0.6, "fiftyTwoWeekHigh": 12.0, "fiftyDayAverage": 0.7203, "twoHundredDayAverage": 2.91767, "currency": "USD", "enterpriseValue": -8878905, "floatShares": 3960588, "sharesOutstanding": 3979970, "sharesShort": 2755, "sharesShortPriorMonth": 15333, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0007, "heldPercentInsiders": 0.00487, "heldPercentInstitutions": 0.06451, "shortRatio": 0.04, "shortPercentOfFloat": 0.0007, "impliedSharesOutstanding": 3979970, "bookValue": 2.404, "priceToBook": 0.2547421, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -8410784, "trailingEps": -6.66, "forwardEps": -1.39, "lastSplitFactor": "1:12", "lastSplitDate": 1689638400, "enterpriseToEbitda": 0.991, "52WeekChange": -0.8998035, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "QNRX", "underlyingSymbol": "QNRX", "shortName": "Quoin Pharmaceuticals, Ltd.", "longName": "Quoin Pharmaceuticals, Ltd.", "firstTradeDateEpochUtc": 1470058200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "32cb2815-c927-3d74-8136-d444e5765139", "messageBoardId": "finmb_593010770", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.6124, "targetHighPrice": 10.0, "targetLowPrice": 2.45, "targetMeanPrice": 5.48, "targetMedianPrice": 4.0, "recommendationMean": 2.3, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 14689972, "totalCashPerShare": 3.691, "ebitda": -8958543, "totalDebt": 3373733, "quickRatio": 3.478, "currentRatio": 3.614, "debtToEquity": 36.97, "returnOnAssets": -0.32759997, "returnOnEquity": -0.83940005, "freeCashflow": -4485781, "operatingCashflow": -7552266, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]